In particular, anlotinib, a multi-kinase TKI targeting VEGFR, FGFR, and PDGFR, was used in combination with chemotherapy for NSCLC patients as a second- or third-line treatment and has proven to be effective and well-tolerated [297,298,299,300]. This evidence concerns the gene KDR and non-small cell lung carcinoma.